"Relyvrio's CENTAUR Data Shows Promising Reduction in ALS Inflammatory Biomarkers"
Treatment with Relyvrio, an oral therapy developed by Amylyx Pharmaceuticals, significantly reduced blood levels of neuroinflammatory biomarkers in people with amyotrophic lateral sclerosis (ALS) as early as three months, according to a post hoc analysis of the CENTAUR trial. The reductions in biomarkers, C-reactive protein (CRP) and YKL-40, were correlated with slowing disease progression. Relyvrio also met its primary goal of slowing functional decline and extended median survival in ALS patients. Further analysis of neuroinflammatory biomarkers is planned in the ongoing Phase 3 PHOENIX trial.